Rani Therapeutics Forms Research Pact with Chugai

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company specializing in oral drug delivery, has announced a significant research agreement with Chugai Pharmaceutical Co., Ltd. This collaboration, initiated on August 13, 2024, involves the assessment of two molecules targeting undisclosed biological objectives. Rani has shown through comprehensive analysis that their RaniPill® delivery technology offers bioavailability comparable to the traditional subcutaneous delivery method for both molecules under study.

Talat Imran, CEO of Rani Therapeutics, expressed enthusiasm about this partnership, emphasizing Chugai's reputation for research excellence and its innovative contributions to patient care. Imran highlighted the synergy between Chugai's drug discovery techniques and Rani's specialization in creating orally administered antibodies, peptides, and large proteins with high bioavailability. Rani Therapeutics has already tested 19 diverse molecules in preclinical settings and successfully completed three Phase 1 trials using the RaniPill® capsule, demonstrating its wide-ranging applicability for delivering biologics.

Tom Igawa, PhD, Head of Research at Chugai Pharmaceutical Co., Ltd., shared similar sentiments, noting Chugai's dedication to developing revolutionary drug discovery methodologies. He acknowledged the potential of Rani’s technology to bring substantial advancements across various programs. Chugai's commitment to innovation is evident in its proprietary antibody engineering technologies, which aim to address unmet medical needs through the creation of novel pharmaceutical products.

Rani Therapeutics is dedicated to transforming how biologics and drugs are administered. Their primary innovation, the RaniPill® capsule, is designed to replace subcutaneous injections or intravenous infusions with oral administration. The company has conducted multiple preclinical and clinical trials to assess the RaniPill® capsule's safety, tolerability, and bioavailability. This novel approach could significantly improve the patient experience by simplifying the administration of complex biologics.

Chugai Pharmaceutical, based in Tokyo, stands out as a prominent research-driven pharmaceutical company with exceptional drug discovery capabilities. The company's strategic independence, combined with its integration within the Roche Group, underscores its commitment to producing groundbreaking pharmaceutical solutions. Chugai focuses on creating drugs that meet unmet medical needs, leveraging its advanced antibody engineering technologies.

This collaboration between Rani Therapeutics and Chugai Pharmaceutical represents a promising venture in the realm of innovative drug delivery systems. Their combined expertise could potentially lead to breakthroughs in how biologics are administered, making treatments more accessible and convenient for patients worldwide. Through this partnership, Rani's RaniPill® technology could pave the way for new methods of oral delivery, reducing the need for traditional injection-based treatments and enhancing patient compliance and comfort.